Anidulafungin - Challenges in development and validation of an LC-MS/MS bioanalytical method validated for regulated clinical studies

Analytical and Bioanalytical Chemistry

Volumn 404, Issue 6-7, 2012, Pages 2043-2055

  Alebic Kolbah, Tanja ^a   Modesitt, Michael S ^b  

^a PFIZER INC   (United States)

^b Pharmaceutical Product Development   (United States)

Author keywords

Anidulafungin; Anidulafungin open ring form; HPLC MS MS; Pediatric blood collection; Regulated bioanalysis; Validation

Indexed keywords

ANIDULAFUNGIN; ANIDULAFUNGIN OPEN-RING FORM; BIOANALYSIS; HPLC-MS/MS; PEDIATRIC BLOOD; VALIDATION;

ACCEPTANCE TESTS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PEDIATRICS; PLASMA (HUMAN); PLASMAS;

CHROMATOGRAPHY;

ANIDULAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN;

ARTICLE; BLOOD; EVALUATION; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INFANT; MALE; MEDICAL RESEARCH; METHODOLOGY; NEWBORN; TANDEM MASS SPECTROMETRY; VALIDATION STUDY;

ANTIFUNGAL AGENTS; BIOMEDICAL RESEARCH; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ECHINOCANDINS; FEMALE; HUMANS; INFANT; INFANT, NEWBORN; MALE; TANDEM MASS SPECTROMETRY;

EID: 84867328095     PISSN: 16182642     EISSN: 16182650     Source Type: Journal    
DOI: 10.1007/s00216-012-6272-4     Document Type: Article

References (13)

1. Raasch RH (2004) Anidulafungin: review of a new echinocandin antifungal agent. Expert Rev Anti Infect Ther 2(4): 499-508
2. Dowell JA, Knebel W, Ludden T, Stogniew M, Krause D, Henkel T (2004) Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal. J Clin Pharmacol 44(6): 590-598. doi:10.1177/009127000426564444/6/ 590
3. Dowell JA, Schranz J, Baruch A, Foster G (2005) Safety and pharmacokinetics of coadministered voriconazole and anidulafungin. J Clin Pharmacol 45(12): 1373-1382. doi:10.1177/0091270005281234
4. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS, Russomanno JH, Shore E, Nicolau DP, Kuti JL (2009) Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 53(12): 5102-5107. doi:10.1128/AAC. 01042-09
5. Sutherland CA, Nicolau DP, Kuti JL (2011) Development of an HPLC method for the determination of anidulafungin in human plasma and saline. J Chromatogr Sci 49(5): 397-400
6. Farowski F, Cornely OA, Vehreschild JJ, Hartmann P, Bauer T, Steinbach A, Ruping MJ, Muller C (2010) Quantitation of azoles and echinocandins in compartments of peripheral blood by liquid chromatography-tandem mass spectrometry. Antimicrob Agents Chemother 54(5): 1815-1819. doi:10.1128/AAC. 01276-09
7. Decosterd LA, Rochat B, Pesse B, Mercier T, Tissot F, Widmer N, Bille J, Calandra T, Zanolari B, Marchetti O (2010) Multiplex ultra-performance liquid chromatography-tandem mass spectrometry method for simultaneous quantification in human plasma of fluconazole, itraconazole, hydroxyitraconazole, posaconazole, voriconazole, voriconazole-N-oxide, anidulafungin, and caspofungin. Antimicrob Agents Chemother 54(12): 5303-5315. doi:10.1128/AAC. 00404-10
8. Martens-Lobenhoffer J, Rupprecht V, Bode-Boger SM (2011) Determination of micafungin and anidulafungin in human plasma: UV- or mass spectrometric quantification? J Chromatogr B Analyt Technol Biomed Life Sci 879(22): 2051-2056. doi:10.1016/j.jchromb.2011.05.033
9. Balkovec JM, Black RM, Hammond ML, Heck JV, Zambias RA, Abruzzo G, Bartizal K, Kropp H, Trainor C, Schwartz RE et al (1992) Synthesis, stability, and biological evaluation of watersoluble prodrugs of a new echinocandin lipopeptide. Discovery of a potential clinical agent for the treatment of systemic candidiasis and Pneumocystis carinii pneumonia (PCP). J Med Chem 35 (1): 194-198
10. Norris T, VanAlsten J, Hubbs S, Ewing M, Cai W, Jorgensen ML, Bordner J, Jensen GO (2008) Commercialization and late-stage development of a semisynthetic antifungal API: anidulafungin/Dfructose (Eraxis). Org Process Res Dev 12(3): 447-455
11. Damle BD, Dowell JA, Walsky RL, Weber GL, Stogniew M, Inskeep PB (2009) In vitro and in vivo studies to characterize the clearance mechanism and potential cytochrome P450 interactions of anidulafungin. Antimicrob Agents Chemother 53(3): 1149-1156. doi:10.1128/AAC. 01279-08
12. US Department of Health and Human Services. Food and Drug Administration (FDA). Center for Drug Evaluation and Research (CDER). Guidance for Industry. Bioanalytical Method Validation. http://www.fda.gov/cder/guidance/4252fnl.htm. Accessed December 2008
13. Fast DM, Kelley M, Viswanathan CT, O'Shaughnessy J, King SP, Chaudhary A, Weiner R, DeStefano AJ, Tang D (2009) Workshop report and follow-up - AAPS workshop on current topics in GLP bioanalysis: assay reproducibility for incurred samples - implications of Crystal City recommendations. AAPS J 11(2): 238-241. doi:10.1208/s 12248-009- 9100-9